Document:

Exhibit 10.2

 

SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT

 

This SECOND AMENDED AND RESTATED EMPLOYMENT
AGREEMENT (the “Agreement”) is entered into as of March 4, 2020 (the “Effective Date”), by and between
Aerojet Rocketdyne Holdings, Inc. (“Aerojet Rocketdyne” or the “Company”), having its principal place of
business at 222 N. Pacific Coast Highway Suite 500, El Segundo, California 90245 and Eileen P. Drake (“Executive”,
and the Company and Executive collectively referred to as the “Parties”).

 

W I T N E S S E T H:

 

WHEREAS, the Company and Executive entered into
an employment agreement, dated as of November 23, 2015 and an amended and restated employment agreement dated as of March 13, 2018;

 

WHEREAS, the Company desires to continue to
employ Executive as the Chief Executive Officer and President (“CEO”) of the Company; and

 

WHEREAS, the Parties desire to amend and restate
the previous amended and restated employment agreement and enter into this Agreement embodying the terms of such continued employment.

 

NOW, THEREFORE, in consideration of the premises
and the mutual covenants and promises of the Parties, the Parties, intending to be legally bound, agree as follows:

 

1.                 
Title and Job Duties.

 

(a)              
Subject to the terms and conditions set forth in this Agreement, the Company agrees to continue to employ Executive as CEO.
In this capacity, Executive shall have the duties, authorities and responsibilities commensurate with the duties, authorities and
responsibilities of persons in similar capacities in similarly sized companies, and such other duties, authorities and responsibilities
as the Board of Directors of the Company (the “Board”) shall designate from time to time that are not inconsistent
with Executive’s position as CEO. Executive shall report directly to the Board and the Chairman of the Board. All employees
of the Company shall report directly to Executive or her designee.

 

(b)              
Executive accepts such employment and agrees, during the term of her employment, to devote her full business and professional
time and energy to the Company. Executive agrees to carry out and abide by all lawful directions of the Board and the Chairman
of the Board that are consistent with her position as Chief Executive Officer.

 

(c)              
Without limiting the generality of the foregoing, Executive shall not, without the written approval of the Company, render
services of a business or commercial nature on her own behalf or on behalf of any other person, firm, or corporation, whether for
compensation or otherwise, during her employment hereunder, provided that the foregoing shall not prevent Executive from (i) serving
on the boards of directors of non-profit organizations and, with the prior written approval of the Board, other for-profit companies,
(ii) participating in charitable, civic, educational, professional, community or industry affairs, and (iii) managing Executive’s
passive personal investments so long as such activities in the aggregate do not materially interfere or conflict with Executive’s
duties or create a potential business or fiduciary conflict.

 

     

    

    

(d)              
Executive may own passive investments in Competing Businesses, defined below, (including, but not limited to, indirect investments
through mutual funds), provided the securities of the Competing Business are publicly traded and Executive does not own or control
more than one percent (1%) of the outstanding voting rights or equity of the Competing Business. “Competing Business”
means any corporation, partnership, limited liability company, university, government agency or other entity or person (other than
the Company) which is engaged in the development, manufacture, marketing, distribution or sale of, or research directed to aerospace
and defense systems and in the Eastern Sacramento area, real estate development.

 

2.                 
Salary and Additional Compensation.

 

(a)              
Base Salary. The Company shall pay to Executive an annual base salary (“Base Salary”) of nine hundred
twenty seven thousand dollars ($927,000), less applicable withholdings and deductions, in accordance with the Company’s normal
payroll procedures, with such base salary effective as of March 7, 2020. The Organization & Compensation Committee (the “Committee”)
of the Board may increase Executive’s annual Base Salary from time to time in its sole and absolute discretion.

 

(b)              
Bonus. Executive shall be eligible for an annual bonus based on a target opportunity pursuant to the Company’s
Short Term Incentive Plan (“Target Bonus”) which shall be adopted annually by the Board. For each fiscal year, Executive’s
Target Bonus shall be one hundred percent (100%) of the annual Base Salary in effect for the then-current fiscal year. The annual
incentive for each fiscal year will be calculated based on the performance metrics for each respective fiscal year, and will be
paid at the same time as when normal course annual incentives amounts are paid. The Committee may adjust Executive’s Target
Bonus for any fiscal year in its sole and absolute discretion.

 

(c)              
Prior Equity Awards. To the extent that shares are unvested, Executive remains eligible to vest in all prior equity
awards pursuant to the terms of the Amended and Restated 2009 Equity and Performance Incentive Plan (the “2009 Plan”),
the Aerojet Rocketdyne 2018 Equity and Performance Incentive Plan (the “2018 Incentive Plan”) and the Aerojet Rocketdyne
2019 Equity and Performance Incentive Plan (the “2019 Incentive Plan”) (the 2009 Plan, 2018 Incentive Plan and 2019
Incentive Plan, including any amendment thereto, successor or replacement equity compensation plan of the Company, the “Plans”)
and any relevant grant agreements.

 

3.                 
(d)Equity Awards. Executive shall be eligible to participate in future grants pursuant to the Plans and other
Company performance incentive plans extended to senior executives of the Company generally, at levels commensurate with Executive’s
position. For each fiscal year, the target opportunity for grants of awards to Executive under the Long-Term Incentive Plan (“LTIP”)
is three hundred fifty percent (350%) of the annual Base Salary in effect for the then-current fiscal year. The Committee may adjust
Executive’s LTIP award target percentages from time to time in its sole and absolute discretion and the specific terms of
any such awards, will, in all cases, be determined by the Committee at the time of the award. Expenses. In accordance with
Company policy, the Company shall reimburse Executive for all reasonable business expenses properly and reasonably incurred and
paid by Executive in the performance of her duties under this Agreement upon her presentment of detailed receipts in the form required
by the Company’s policy.

 

    2

    

    

4.                 
Benefits.

 

(a)              
Vacation. Executive shall be entitled to four weeks’ vacation.

 

(b)              
Health Insurance and Other Plans. Executive shall be eligible to participate in the Company’s medical, dental,
short and long-term incentive plans, and other employee benefit programs, if any, that are provided by the Company for its employees
generally, at levels commensurate with Executive’s position, in accordance with the provisions of any such plans, as the
same may be in effect from time to time.

 

5.                 
Term. The terms set forth in this Agreement will commence on the Effective Date and shall remain in effect for one
(1) year except as otherwise provided in this Agreement. The term of employment shall thereafter be deemed to be automatically
extended, upon the same terms and conditions, for successive periods of one year, unless either party, at least 60 days prior to
the expiration of the original term or any extended term, shall give written notice to the other of its intention not to renew
such employment. The period during which Executive is employed pursuant to this Agreement, including any extension thereof in accordance
with the preceding sentence, shall be referred to as the “Employment Period”.

 

6.                 
Termination.

 

(a)              
Termination at the Company’s Election.

 

(i) 
For Cause. At the election of the Company, Executive’s employment may be terminated for Cause (as defined below)
upon written notice to Executive pursuant to Section 10 of this Agreement. For purposes of this Agreement, “Cause”
for termination shall mean that Executive: (A) pleads “guilty” or “no contest” to or is indicted for or
convicted of a felony under federal or state law or as a crime under federal or state law which involves Executive’s fraud
or dishonesty; (B) in carrying out her duties, engages in conduct that constitutes gross negligence or willful misconduct; (C)
fails to reasonably and materially perform the responsibilities of her position; (D) engages in misconduct that causes material
harm to the reputation of the Company; or (E) materially breaches any term of this Agreement or written policy of the Company,
provided that if the Company provides written notice of Cause pursuant to (C) through (E), Executive shall be given thirty (30)
days from the date of such written notice to cure such conduct.

 

    3

    

    

(ii)                      
Upon Disability, Death or Without Cause. At the election of the Company, Executive’s employment may be terminated
without Cause: (A) should Executive become physically or mentally unable to perform her duties for the Company and such incapacity
has continued for a total of ninety (90) consecutive days or any one hundred eighty (180) days in a period of three hundred sixty-five
(365) consecutive days (a “Disability”); (B) upon Executive’s death (“Death”); or (C) upon thirty
(30) days’ written notice for any other reason.

 

(b)              
Termination at Executive’s Election.

 

(i) 
For Good Reason. At Executive’s election, Executive’s employment may be terminated for Good Reason (as
defined below) by providing notice to the Company pursuant to Section 10 of this Agreement. For purposes of this Agreement, “Good
Reason” shall be deemed to exist if the following actions occur without Executive’s consent: (A) a material diminution
in Executive’s Base Salary or Target Bonus, (B) a requirement that Executive be based anywhere other than within 25 miles
of Los Angeles, California, or (C) a material diminution in Executive’s title, duties, responsibilities, authority or reporting
obligations from those in effect on the Effective Date (it being understood that Executive’s obligation to report to the
Board and the Board’s exercise of its final authority over Company matters shall not give rise to any such claim of diminution);
provided, however, that no event shall constitute Good Reason unless Executive has notified the Company in writing of Executive’s
intention to so terminate Executive’s employment, such notice: (i) to state in detail the particular acts or failures to
act that constitute the grounds on which the proposed termination for Good Reason is based, (ii) to be given within sixty (60)
days after the first occurrence of such acts or failures to act, and (iii) the Company shall have thirty (30) days following receipt
of such notice to cure such acts or failures to act in all material respects. If the Company has not cured such acts or failures
to act within the thirty (30) day cure period, then Executive’s employment shall be immediately terminated for Good Reason.

 

(ii)                      
Voluntary Resignation. Notwithstanding anything contained elsewhere in this Agreement to the contrary, Executive
may terminate her employment at any time and for any reason whatsoever or for no reason at all in Executive’s sole discretion
by giving thirty (30) days written notice pursuant to Section 10 of this Agreement.

 

7.                 
Payments upon Termination of Employment.

 

(a)              
Termination for Cause or Resignation without Good Reason. If Executive’s employment is terminated by the Company
for “Cause” or if Executive resigns from her employment other than for “Good Reason”, Executive shall be
entitled to the following amounts only: (A) payment of her Base Salary accrued up to and including the date of termination or resignation,
to be paid at termination, (B) payment in lieu of any accrued but unused vacation time, in accordance with the Company’s
vacation policy, (C) payment of any unreimbursed expenses in accordance with the Company’s business reimbursement policy;
and (D) payments and benefits under any Company benefit plan, program or policy that Executive participated in during employment
and paid pursuant to the terms of such plan, program and policy (collectively, the “Accrued Obligations”). Unless otherwise
required by law under the terms of any applicable Company benefit plan, program or policy, the benefits pursuant to Section 4(a)
and (b) of this agreement will terminate at the end of the month of termination of employment. For the avoidance of doubt, (i)
Executive will not be entitled to receive any bonus payments other than those fully earned and paid by the date of termination;
(ii) all vesting on awards granted to Executive under the Plans or other Company performance or incentive plan will cease; and
(iii) any unvested awards granted under the Plans or other Company performance or incentive plan will be forfeited.

 

    4

    

    

(b)              
Termination due to Death or Disability. If Executive’s employment is terminated at any time due to her Death
or Disability, Executive shall be entitled to receive the Accrued Obligations and severance payments and benefits equal to the
following: (i) subject to Section 17, twelve (12) months of Executive’s Base Salary paid in installments; (ii) any bonuses
earned and paid by the date of termination; (iii) to the extent unvested at the time of Executive’s termination of employment
pursuant to the terms of the applicable grant agreements, immediate full vesting of all of Executive’s equity awards under
the Plans (at the maximum level of performance, if applicable); (iv) outplacement services provided by the Company-designated outplacement
firm for a period of eighteen (18) months starting no later than ninety (90) days from Executive’s date of termination with
a maximum value of $25,000; (v) in the case of Death, Executive shall receive life insurance benefits paid in accordance with the
terms of the policy and coverage in which Executive was enrolled before the date of Death; (vi) in the case of termination due
to Disability, the Company shall pay for the premiums associated with six (6) months of Executive’s continued participation,
without any required contributions from Executive (but subject to all other plan and policy terms) in Executive’s Company
provided life insurance policy in which Executive is enrolled before the date of termination; and (vii) provided Executive timely
elects and is eligible for COBRA coverage, the Company shall pay for the premiums associated with six (6) months of Executive’s
continued participation, without any required contributions from Executive (but subject to all other plan terms, including co-payments
and deductibles) in the Aerojet Rocketdyne Medical Plan, Aerojet Rocketdyne Dental Plan, and the Aerojet Rocketdyne Vision Plan
(the “Benefit Plans”) in which Executive is enrolled before the date of termination. Payment of the Base Salary component
of Executive’s severance shall be made on regular paydays.

 

(c)              
Termination by the Company for Reasons other than Cause or Termination by Executive for Good Reason. If Executive’s
employment is terminated at the Company’s election at any time for reasons other than Cause or by Executive for Good Reason
and neither Section 7(b) nor Section 7(d) is applicable at the time of Executive’s termination of employment, Executive shall
be entitled to receive the Accrued Obligations and severance payments and benefits equal to the following: (i) subject to Section
17, twelve (12) months of Executive’s Base Salary paid in installments; (ii) to the extent unvested at the time of Executive’s
termination of employment pursuant to the terms of the applicable grant agreements, immediate full vesting of all of Executive’s
equity awards under the Plans (at the maximum level of performance, if applicable); (iii) Executive will have the opportunity to
continue to participate in the Company provided life insurance policy in which Executive is enrolled before the date of termination
at an amount of 1x Base Salary for a period of twelve (12) months following the date of termination; (iv) provided Executive timely
elects and is eligible for COBRA coverage, the Company shall pay for the premiums associated with eighteen (18) months of Executive’s
continued participation, without any required contributions from Executive (but subject to all other plan terms, including co-payments
and deductibles) in the Aerojet Rocketdyne Medical Plan, Aerojet Rocketdyne Dental Plan, and the Aerojet Rocketdyne Vision Plan
(the “Benefit Plans”) in which Executive is enrolled prior to the date of termination; and (v) outplacement services
provided by the Company-designated outplacement firm for a period of eighteen (18) months starting no later than ninety (90) days
from Executive’s date of termination with a maximum value of $25,000. Payment of the Base Salary component of Executive’s
severance shall be made on regular paydays. Subject to Executive’s execution and delivery of a general release (that is no
longer subject to revocation under applicable law) of the Company, its parents, subsidiaries and affiliates and each of its officers,
directors, employees, agents, successors and assigns in the form attached as Exhibit A (the “General Release”)
all payments and/or grants under this Section 7(c) shall begin on the first payroll period that is sixty (60) days after Executive’s
termination of employment with the first payment for severance payments described in Section 7(c)(i) to include payment of any
amounts otherwise due as of the date of termination.

 

    5

    

    

(d)              
Termination in Connection with a Change in Control. Notwithstanding Section 7(c) above, if Executive’s employment
is terminated by the Company without Cause (including due to a Death or Disability) or by Executive for Good Reason within six
(6) months prior to (or, if earlier, following the signing of a definitive agreement that if consummated would result in a Change
in Control (as defined below); provided such Change in Control subsequently occurs) or twenty-four (24) months following a Change
in Control then Executive shall be entitled to the following payments and benefits subject to Section 17: (i) the Accrued Obligations;
(ii) annual Target Bonus for the pro-rated portion of the fiscal year prior to the Change in Control paid based on the greater
of target or actual level of performance in a lump sum; (iii) a severance payment equal to three (3) times the sum of (y) Executive’s
Base Salary, plus (z) annual Target Bonus paid in a lump sum; (iv) to the extent unvested at the time of Executive’s termination
of employment pursuant to the terms of the applicable grant agreements, immediate full vesting of all of Executive’s equity
awards under the Plans (at the maximum level of performance, if applicable); (v) Executive will have the opportunity to continue
to participate in the Company provided life insurance policy in which Executive is enrolled before the date of termination at an
amount of 1x Base Salary for a period of twelve (12) months following the date of termination; (vi) provided Executive timely elects
and is eligible for COBRA coverage, the Company shall pay for the premiums associated with twenty-four (24) months of Executive’s
continued participation, without any required contributions from Executive (but subject to all other plan terms, including co-payments
and deductibles) in the Aerojet Rocketdyne Medical Plan, Aerojet Rocketdyne Dental Plan, Aerojet Rocketdyne’s Executive Physical
Program and the Aerojet Rocketdyne Vision Plan (the “Benefit Plans”) in which Executive is enrolled prior to the date
of termination; and (vii) outplacement services provided by the Company-designated outplacement firm for a period of eighteen (18)
months starting no later than ninety (90) days from Executive’s date of termination with a maximum value of $25,000. Subject
to Executive’s execution and delivery of the General Release (provided, that such General Release was not previously executed
and delivered), all payments and/or grants under this Section 7(d) shall begin on the first payroll period that is sixty (60) days
after Executive’s termination of employment or, if applicable, upon the consummation of a Change in Control. For purposes
of this Agreement, a Change in Control shall have the meaning prescribed to such term in the Company’s Executive Change in
Control Severance Policy (the “Severance Policy”) as in effect on the date hereto; provided, however, and notwithstanding
the foregoing, in the event a “Change in Control” (or such similar term) were to occur under the Severance Policy as
subsequently amended or under a successor or replacement equity compensation plan adopted by the Company, a Change in Control shall
be deemed to have occurred under this Agreement.

 

 

 

 

 

 

 

 

 

    6

    

    

(e)              
Termination of the Term. If Executive’s employment terminates pursuant to written notice by the Company of
its intention not to renew the term as provided in Section 5, then Executive shall be entitled to the payments set forth in 7(c)
above.

 

(f)               
No Mitigation; No Set-Off. The Company’s obligation to pay Executive the amounts provided and to make the arrangements
provided shall not be subject to set-off, counterclaim or recoupment of amounts owed by Executive to the Company or its affiliates.
Executive shall not be required to mitigate the amount of any payment provided for pursuant to this Agreement by seeking other
employment, and no amounts otherwise earned shall be set-off against the amounts due.

 

8.                 
Confidentiality Agreement and Assignment of Intellectual Property.

 

(a)              
Executive understands that during the Employment Period, she may have access to unpublished and otherwise confidential information
both of a technical and non-technical nature, relating to the business of the Company and any of its parents, subsidiaries, divisions,
affiliates (collectively, “Affiliated Entities”), or clients, including without limitation any of their actual or anticipated
business, research or development, any of their technology or the implementation or exploitation thereof, including without limitation
information Executive and others have collected, obtained or created, information pertaining to clients, accounts, vendors, prices,
costs, materials, processes, codes, material results, technology, system designs, system specifications, materials of construction,
trade secrets and equipment designs, including information disclosed to the Company by others under agreements to hold such information
confidential (collectively, the “Confidential Information”). Executive agrees to observe all Company policies and procedures
concerning such Confidential Information. Executive further agrees not to disclose or use, either during her employment or at any
time thereafter, any Confidential Information for any purpose, including without limitation any competitive purpose, unless authorized
to do so by the Company in writing, except that she may disclose and use such information in the good faith performance of her
duties for the Company. Executive’s obligations under this Agreement will continue with respect to Confidential Information,
whether or not her employment is terminated, until such information becomes generally available from public sources through no
fault of Executive or any representative of Executive. Notwithstanding the foregoing, however, Executive shall be permitted to
disclose Confidential Information as may be required by a subpoena or other governmental order, provided that she first notifies
the Company of such subpoena, order or other requirement and such that the Company has the opportunity to obtain a protective order
or other appropriate remedy.

 

    7

    

    

(b)              
During Executive’s employment, upon the Company’s request, or upon the termination of her employment for any
reason, Executive will promptly deliver to the Company all documents, records, files, notebooks, manuals, letters, notes, reports,
customer and supplier lists, cost and profit data, e-mail, apparatus, computers, blackberries, smartphones, tablets or other PDAs,
hardware, software, drawings, blueprints, and any other material of the Company or any of its Affiliated Entities or clients, including
all materials pertaining to Confidential Information developed by Executive or others, and all copies of such materials, whether
of a technical, business or fiscal nature, whether on the hard drive of a laptop or desktop computer, in hard copy, disk or any
other format, which are in her possession, custody or control. Executive may retain Executive’s rolodex and similar address
books, provided, that such items only include contact information.

 

(c)              
Executive will promptly disclose to the Company any idea, invention, discovery or improvement, whether patentable or not
(“Creations”), conceived or made by her alone or with others at any time during her employment. Executive agrees
that the Company owns any such Creations, conceived or made by Executive alone or with others at any time during her employment,
and Executive assigns and agrees to assign to the Company all rights she has or may acquire therein and agrees to execute any and
all applications, assignments and other instruments relating thereto which the Company deems necessary or desirable. These obligations
shall continue beyond the termination of her employment with respect to Creations and derivatives of such Creations conceived or
made during her employment with the Company. The Company and Executive understand that the obligation to assign Creations to the
Company shall not apply to any Creation which is developed entirely on her own time without using any of the Company’s equipment,
supplies, facilities, and/or Confidential Information unless such Creation (a) relates in any way to the business or to the
current or anticipated research or development of the Company or any of its Affiliated Entities; or (b) results in any way
from her work at the Company.

 

(d)              
Executive will not assert any rights to any invention, discovery, idea or improvement relating to the business of the Company
or any of its Affiliated Entities or to her duties hereunder as having been made or acquired by Executive before her work for the
Company, except for the matters, if any, described in Exhibit B to this Agreement.

 

(e)           
During the Employment Period, if Executive incorporates into a product or process of the Company or any of its Affiliated
Entities anything listed or described in Exhibit B, the Company is granted and shall have a non-exclusive, royalty-free,
irrevocable, perpetual, worldwide license (with the right to grant and authorize sublicenses) to make, have made, modify, use,
sell, offer to sell, import, reproduce, distribute, publish, prepare derivative works of, display, perform publicly and by means
of digital audio transmission and otherwise exploit as part of or in connection with any product, process or machine.

 

(f)               
Executive agrees to cooperate fully with the Company, both during and after her employment with the Company, with respect
to the procurement, maintenance and enforcement of copyrights, patents, trademarks and other intellectual property rights (both
in the United States and foreign countries) relating to such Creations. Executive shall sign all papers, including, without limitation,
copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights and powers
of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Creations. Executive
further agrees that if the Company is unable, after reasonable effort, to secure Executive’s signature on any such papers,
any officer of the Company shall be entitled to execute such papers as her agent and attorney-in-fact and Executive irrevocably
designates and appoints each officer of the Company as her agent and attorney-in-fact to execute any such papers on her behalf
and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in
any Creations, under the conditions described in this paragraph.

 

    8

    

    

9.                 
Representation and Warranty. Executive represents and warrants to the Company that she is not subject to any agreement
restricting her ability to enter into this Agreement and fully carry out her duties and responsibilities. To the extent that Executive
continues to be bound by confidentiality, non-disparagement obligations with regard to her former employer, the Company and Executive
agree that neither shall require Executive to disclose any confidential information of any prior employer of Executive or misappropriate
any intellectual property belonging to any other person or entity during the Employment Period.

 

10.             
Notice. Any notice or other communication required or permitted to be given to the Parties shall be deemed to have
been given if personally delivered, if sent by nationally recognized overnight courier or if mailed by certified or registered
mail, return receipt requested, first class postage prepaid, and addressed as follows:

 

	(a)		If to Executive, to:

 

the address shown on the records of the Company.

 

	(b)		If to the Company, to:

 

Aerojet Rocketdyne Holdings, Inc.

222 N. Pacific Coast Highway Suite 500

El Segundo, California 90245

Attention: Executive Chairman of the Board

 

with a copy to:

 

Aerojet Rocketdyne Holdings, Inc.

222 N. Pacific Coast Highway Suite 500

El Segundo, California 90245

Attention: Vice President, Human Resources

 

11.             
Severability. If any provision of this Agreement is declared void or unenforceable by a court of competent jurisdiction,
all other provisions shall nonetheless remain in full force and effect.

 

12.             
Governing Law and Arbitration. This Agreement shall be governed by, and construed and enforced in accordance with,
the laws of the State of California, without regard to the conflict of laws provisions thereof. Any action, suit or other legal
proceeding which is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be submitted
to final and binding arbitration pursuant to the Employment Arbitration Rules of the American Arbitration Association before a
single arbitrator, who is agreed upon by the Parties, and who is a retired state or federal court judge. The arbitration shall
take place in Los Angeles, California. The arbitrator will have the authority to permit discovery and to follow the procedures
that she or she determines to be appropriate, as provided for under California law. The arbitrator will have no power to award
consequential (including lost profits), punitive or exemplary damages. Such submission to arbitrate shall be the sole and exclusive
remedy available to Executive or the Company. The filing Party shall bear filing fees for the arbitration and each Party shall
bear its own legal fees and costs resulting from the arbitration, unless a contract or statute provides for recovery to the prevailing
party. The judgment on the award rendered by the arbitrator shall be binding upon the Parties and may be entered in any court having
jurisdiction. Neither party may seek judicial review of the decision imposed by the arbitrator.

 

    9

    

    

13.             
Indemnification and Liability Insurance. The Company shall indemnify, and if applicable, defend Executive and provide
Executive with liability insurance pursuant to the terms of the Certificate of Incorporation of Aerojet Rocketdyne Holdings, Inc.
and the Aerojet Rocketdyne Holdings, Inc. Bylaws or, if the terms of the Certificate of Incorporation of Aerojet Rocketdyne Holdings,
Inc. and the Aerojet Rocketdyne Holdings, Inc. Bylaws are no longer in effect, then pursuant to the terms then in effect for directors
and officers of the Company.

 

14.             
Waiver. The waiver by either Party of a breach of any provision of this Agreement shall not be or be construed as
a waiver of any subsequent breach. The failure of a Party to insist upon strict adherence to any provision of this Agreement on
one or more occasions shall not be considered a waiver or deprive that Party of the right thereafter to insist upon strict adherence
to that provision or any other provision of this Agreement. Any waiver must be in writing.

 

15.             
Assignment. This Agreement is a personal contract and Executive may not sell, transfer, assign, pledge or hypothecate
her rights, interests and obligations hereunder. Except as otherwise herein expressly provided, this Agreement shall be binding
upon and shall inure to the benefit of Executive and her personal representatives and shall inure to the benefit of and be binding
upon the Company and its successors and assigns, except that the Company may not assign this Agreement without Executive's prior
written consent, except to an acquirer of all or substantially all of the assets of the Company other than the real estate assets
and upon written assumption of the obligations of this Agreement.

 

16.             
Entire Agreement. This Agreement (together with the attached Exhibits) embodies all of the representations, warranties,
and agreements between the Parties relating to Executive’s employment with the Company. No other representations, warranties,
covenants, understandings, or agreements exist between the Parties relating to Executive’s employment. This Agreement shall
supersede all prior agreements, written or oral, relating to Executive’s employment. This Agreement may not be amended or
modified except by a writing signed by the Parties.

 

    10

    

    

17.             
Code Section 409A Compliance.

 

(a)              
The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from, Internal Revenue
Code (“Code”) Section 409A and the regulations and guidance promulgated thereunder (collectively “Code Section
409A”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.
If Executive notifies the Company (with specificity as to the reason therefore) that Executive believes that as a result of subsequent
published guidance issued by the I.R.S. upon which taxpayers generally rely, any provision of this Agreement (or of any award of
compensation, including equity compensation or benefits) would cause Executive to incur any additional tax or interest under Code
Section 409A and the Company concurs with such belief or the Company independently makes such determination, the Company shall,
after consulting with Executive, reform such provision to try to comply with Code Section 409A through good faith modifications
to the minimum extent reasonably appropriate to conform with Code Section 409A. To the extent that any provision hereof is modified
in order to comply with Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably
possible, maintain the original intent and economic benefit to Executive and the Company and is tax neutral to the Company of the
applicable provision without violating the provisions of Code Section 409A.

 

(b)              
A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing
for the payment of any amounts or benefits upon or following a termination of employment that are considered “nonqualified
deferred compensation” under Code Section 409A unless such termination is also a “separation from service” within
the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,”
“termination of employment” or like terms shall mean “separation from service.” If Executive is deemed
on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B),
then with regard to any payment that is considered non-qualified deferred compensation under Code Section 409A payable on account
of a “separation from service,” such payment or benefit shall be made or provided at the date which is the earlier
of (A) the expiration of the six (6)-month period measured from the date of such “separation from service” of Executive,
and (B) thirty (30) days from the date of Executive’s death (the “Delay Period”). Upon the expiration
of the Delay Period, all payments and benefits delayed pursuant to this Section 17 (whether they would have otherwise been payable
in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Executive in a lump sum without
interest on the first business day following the Delay Period, and any remaining payments and benefits due under this Agreement
shall be paid or provided in accordance with the normal payment dates specified for them herein.

 

(c)              
With regard to any provision that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted
by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another
benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not
affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, provided that the
foregoing clause (ii) shall not be violated without regard to expenses reimbursed under any arrangement covered by Internal Revenue
Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and
(iii) such payments shall be made on or before the last day of Executive’s taxable year following the taxable year in which
the expense occurred. Any tax gross-up payment as provided for in this Agreement shall be made in any event no later than the end
of the calendar year immediately following the calendar year in which Executive remits the related taxes, and any reimbursement
of expenses incurred due to a tax audit or litigation shall be made no later than the end of the calendar year immediately following
the calendar year in which the taxes that are the subject of the audit or litigation are remitted to the taxing authority, or,
if no taxes are to be remitted, the end of the calendar year following the calendar year in which the audit or litigation is completed.

 

    11

    

    

(d)              
For purposes of Code Section 409A, Executive’s right to receive any installment payments pursuant to this Agreement
shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies
a payment period with reference to a number of days (e.g., “within sixty (60) days following the date of termination”),
the actual date of payment within the specified period shall be within the sole discretion of the Company.

 

18.             
Limitation on Benefits. Notwithstanding anything to the contrary contained in this Agreement, to the extent that
any of the payments and benefits provided for under this Agreement or any other agreement or arrangement between the Company and
Executive, or any arrangement or agreement with any person whose actions result in a change of ownership of effective control or
a change in ownership of a substantial portion of the assets of the corporation covered by Section 280G(b)(2) (collectively, the
“Payments”) (i) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii)
but for this Section 18, would be subject to the excise tax imposed by Section 4999 of the Code, then the Payments shall be payable
either (i) in full or (ii) as to such lesser amount which would result in no portion of such Payments being subject to excise tax
under Section 4999 of the Code; whichever of the foregoing amounts, taking into account the applicable federal, state and local
income taxes, payroll taxes and the excise tax imposed by Section 4999, results in Executive’s receipt on an after-tax basis,
of the greater amount of payment and benefits. Any reduction under clause (ii) of the preceding sentence shall be done first by
reducing any cash severance payments with the last payment reduced first; next any equity or equity derivatives that are included
at full value rather than accelerated value; next any equity or equity derivatives based on acceleration value shall be reduced
with the highest value reduced first. Notwithstanding the foregoing, to the extent that the Company and Executive agree that it
would not violate Code Section 409A or impact the ability of the parties to reduce the amounts receivable, Executive may prescribe
a different order of reduction. Unless Executive and the Company otherwise agree in writing, any determination required under this
Section 18 shall be made in writing by the Company's independent public accountants (the "Accountants"), whose determination
shall be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations required
by this Section 18, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely
in reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive
shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination
under this Section 18. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations
contemplated by this Section 18. If the limitation set forth in this Section 18 is applied to reduce an amount payable to Executive,
and the Internal Revenue Service successfully asserts that, despite the reduction, Executive has nonetheless received payments
which are in excess of the maximum amount that could have been paid to Executive without being subjected to any excise tax, then,
unless it would be unlawful for the Company to make such a loan or similar extension of credit to Executive, Executive may repay
such excess amount to the Company as though such amount constitutes a loan to Executive made at the date of payment of such excess
amount, bearing interest at 120% of the applicable federal rate (as determined under Section 1274(d) of the Code in respect of
such loan), provided that if the recalculation of the higher amount was then redone based on the IRS position and Executive would
net more if no reduction took place, such reduction shall be cancelled and the full amount paid to Executive in a lump sum within
thirty (30) days of the IRS assessment becoming final, unless this proviso would negate the ability to use the reduction if this
was not implemented or caused a violation of Code Section 409A, in which case this proviso shall be null and void.

 

    12

    

    

[Signature page follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    13

    

    

IN WITNESS WHEREOF, the Parties have caused
this Agreement to be duly executed and delivered on the date above.

 

	 	AEROJET ROCKETDYNE HOLDINGS, INC.
	 	 
	 	 
	 	 
	 	By:	
        /s/ Arjun Kampani

	 	 	Name:	Arjun L. Kampani
	 	 	Title:	Vice President, General Counsel and Secretary
	 	 
	Agreed to and Accepted:	 
	 	 
	 	 
	
        /s/ Eileen Drake
	 
	Eileen P. Drake	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    14

    

    

EXHIBIT A

 

AGREEMENT AND RELEASE

 

Agreement and Release (“Agreement”)
executed this ___ day of ______, 20__, by and between Eileen P. Drake (“Executive”) with an address at ___________________
and Aerojet Rocketdyne Holdings, Inc., its parents, subsidiaries and affiliates (the “Company”) with an address at
222 N. Pacific Coast Highway, Suite 500, El Segundo, California 90245.

 

1.                 
Executive’s employment shall be terminated effective ________ (“Termination Date”). As of that date, Executive’s
duties, responsibilities, office and title shall cease. Capitalized terms used without definition in this Agreement shall have
the meanings set forth in the Second Amended and Restated Employment Agreement by and between Executive and the Company, dated
_________, 2020 (the “Employment Agreement”).

 

2.                 
(a)If Executive’s employment terminates pursuant to Section 6(a)(ii) (Death, Disability or without Cause) or 6(b)(i)
(for Good Reason) of the Employment Agreement and Section 7(d) of the Employment Agreement is not applicable as of the Termination
Date, then within ten days of the Release Effective Date, defined below, the Company shall begin to pay to Executive the payments
and benefits described in Section 7(b) or Section 7(c) as applicable, of the Employment Agreement in accordance with the Company’s
standard payroll procedures and on regular paydays.

 

(a)              
Notwithstanding Paragraph 2(a) above, if Executive’s employment is terminated by the Company without Cause or by Executive
for Good Reason within eighteen (18) months following a Change in Control, then Executive shall be entitled to the payments and
benefits described in Section 7(d) of the Employment Agreement.

 

(b)              
The Company and Executive agree that in the event that any of the payments in this Paragraph 2 constitute deferred compensation
within the meaning of Section 409(A) of the Internal Revenue Code of 1986, as amended (the “Code”), and Executive is
at such time a specified employee, such payment or payments that constitute nonqualified deferred compensation within the meaning
of the Code shall not be made prior to the date which is the earlier of (A) the expiration of the six (6)-month period measured
from the date of such “separation from service” (within the meaning of the Code) of Executive, and (B) thirty (30)
days from the date of Executive’s death.

 

3.                 
Executive agrees and acknowledges that the payments and/or benefits provided in Paragraph 2 above exceed any payments and
benefits to which Executive would otherwise be entitled under any policy, plan, and/or procedure of the Company absent her signing
this Agreement. Executive acknowledges that she has been paid for work performed up to and including the Termination Date and for
accrued but unused vacation.

 

4.                 
Executive shall have up to twenty-one (21) days from the date of her receipt of this Agreement to consider the terms and
conditions of this Agreement. Executive may accept this Agreement at any time within the twenty-one (21) day period by executing
it before a notary and returning it to the Chairman of the Board of Directors, Aerojet Rocketdyne Holdings, Inc., 222 N. Pacific
Coast Highway, El Segundo, California 90245, no later than 5:00 p.m. on the twenty-first (21st) day after Executive’s receipt
of this Agreement. Thereafter, Executive will have seven (7) days to revoke this Agreement by stating her desire to do so in writing
to the Chairman of the Board of Directors at the address listed above, and delivering it to the Chairman of the Board of Directors
no later than 5:00 p.m. on the seventh (7th) day following the date Executive signs this Agreement. The effective date
of this Agreement shall be the eighth (8th) day following Executive’s signing of this Agreement (the “Release
Effective Date”), provided Executive does not revoke the Agreement during the revocation period. In the event Executive does
not accept this Agreement as set forth above, or in the event Executive revokes this Agreement during the revocation period, this
Agreement, including but not limited to the obligation of the Company and its subsidiaries and affiliates to provide the payment
and/or benefits referred to in Paragraph 2 above, shall automatically be deemed null and void.

 

    15

    

    

5.                 
(a)In consideration of the payment and/or benefits referred to in Paragraph 2 above, Executive for herself and for her
heirs, executors, and assigns (collectively referred to as the “Releasors”), forever releases and discharges the Company
and any and all of its parent corporations, subsidiaries, divisions, affiliated entities, predecessors, successors and assigns,
and any and all of its or their employee benefit and/or pension plans or funds, and any of its or their past or present officers,
directors, stockholders, agents, trustees, administrators, employees or assigns (whether acting as agents for such entities or
in their individual capacities), (collectively referred to as the “Releasees”), from any and all claims, demands, causes
of action, fees and liabilities of any kind whatsoever (based upon any legal or equitable theory, whether contractual, common-law,
statutory, decisional, federal, state, local or otherwise), whether known or unknown, which Releasors ever had, now have or may
have against the Releasees by reason of any actual or alleged act, omission, transaction, practice, conduct, occurrence, or other
matter from the beginning of the world up to and including the Release Effective Date, except for the obligations of the Company
under this Agreement.

 

(b)              
Without limiting the generality of the foregoing subparagraph (a), this Agreement is intended to and shall release the Releasees
from any and all claims arising out of Executive’s employment with Releasees and/or the termination of Executive’s
employment, including but not limited to any claim(s) under or arising out of (i) Title VII of the Civil Rights Act of 1964, as
amended; (ii) the Americans with Disabilities Act, as amended; (iii) the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”) (excluding claims for accrued, vested benefits under any employee benefit plan of the Company in accordance
with the terms of such plan and applicable law); (iv) the Age Discrimination in Employment Act, as amended, or the Older Workers
Benefit Protection Act; (v) the California Fair Employment Practices and Housing Act; (vi) Section 806 of the Sarbanes Oxley Act
of 2002; (vii) alleged discrimination or retaliation in employment (whether based on federal, state or local law, statutory or
decisional); (viii) the terms and conditions of Executive’s employment with the Company, the termination of such employment,
and/or any of the events relating directly or indirectly to or surrounding that termination; and (ix) any law (statutory or decisional)
providing for attorneys’ fees, costs, disbursements and/or the like.

 

(c)              
As a further consideration and inducement for this Agreement, to the extent permitted by law, Executive hereby waives and
releases any and all rights under Section 1542 of the California Civil Code or any analogous state, local, or federal law, statute,
rule, order or regulation that Executive had or may have with respect to the Releasees. California Civil Code Section 1542 reads
as follows:

 

    16

    

    

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR
DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE
MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

 

Executive hereby expressly agrees that this
Agreement shall extend and apply to all unknown, unsuspected and unanticipated injuries and damages, as well as any that are now
disclosed, arising prior to Executive’s execution of this Agreement. This release does not extend to those rights, which
as a matter of law cannot be waived, including but not limited to unwaivable rights Executive may have under the California Labor
Code. Nothing in this Agreement shall limit Executive’s right to file a charge or complaint with any state or federal agency
or to participate or cooperate in such a manner.

 

(d)              
Notwithstanding the foregoing, nothing in this Agreement shall be construed to prevent Executive from filing a charge with
or participating in an investigation conducted by any governmental agency, including, without limitation, the United States Equal
Employment Opportunity Commission (“EEOC”) or applicable state or city fair employment practices agency, to the extent
required or permitted by law. Nevertheless, Executive understands and agrees that she is waiving any relief available (including,
for example, monetary damages or reinstatement), under any of the claims and/or causes of action waived in Paragraphs 5(a) and
(b), including but not limited to financial benefit or monetary recovery from any lawsuit filed or settlement reached by the EEOC
or anyone else with respect to any claims released and waived in this Agreement.

 

(e)              
Nothing in this Agreement shall release Executive’s rights (i) as a stockholder of the Company; (ii) to any claims
that arise following the execution of this Agreement; (ii) to payment of the Accrued Obligations (as defined in the Employment
Agreement); (iii) to payment of the severance payments and benefits described in Section 2 of this Agreement; (iv) to indemnification
pursuant to the terms set forth in Section 13 of the Employment Agreement and pursuant to any other agreements currently in effect
indemnifying Executive; (v) to any claims for accrued vested benefits or rights under any other employee benefit plan, policy or
arrangement (whether tax-qualified or not) maintained by the Company; (vi) to equity awards that are vested or which may vest under
any equity, equity-based, profits interest, stock option, or similar plans, agreements, employment agreements and/or notices to
the extent set forth in such awards or as otherwise provided for in such documents, which awards shall be subject to all the terms
and conditions of such document.

 

6.                  (a)Executive agrees that she has not and will not engage in any conduct that is injurious to the Company’s or the
Releasees’ reputation or interest, including but not limited to publicly disparaging (or inducing or encouraging others
to publicly disparage) the Company or the Releasees. The foregoing shall not be violated by truthful testimony, if provided
pursuant to the terms of Section 7(b).

 

    17

    

    

(b)              
Executive acknowledges that she has returned to the Company any and all originals and copies of documents, materials, records,
credit cards, keys, building passes, computers, smartphones, tablets, PDAs and other electronic devices or other items in her possession
or control belonging to the Company or containing proprietary information relating to the Company pursuant to Section 8(b) of the
Employment Agreement. Executive may retain Executive’s rolodex and similar address books, provided, that such items only
include contact information.

 

(c)              
Executive acknowledges that the terms of Section 8, Confidentiality Agreement and Assignment of Intellectual Property, of
the Employment Agreement are incorporated herein by reference, and Executive agrees and acknowledges that she is bound by its terms.

 

7.                 
(a)Executive will cooperate with the Company and/or its subsidiaries and affiliates and its/their counsel in connection
with any investigation, administrative proceeding or litigation relating to any matter in which Executive was involved or of which
Executive has knowledge.

 

(b)              
Executive agrees that, in the event she is subpoenaed by any person or entity (including, but not limited to, any government
agency) to give testimony (in a deposition, court proceeding or otherwise) that in any way relates to Executive’s employment
with the Company, she will give prompt notice of such request to the Chairman of the Board of Directors, Aerojet Rocketdyne Holdings,
Inc., and will make no disclosure until the Company has had a reasonable opportunity to contest the right of the requesting person
or entity to such disclosure, provided that nothing in this Agreement shall prevent Executive from complying with the requirements
of the law.

 

8.                 
Before public announcement, the terms and conditions of this Agreement are and shall be deemed to be confidential, and shall
not be disclosed by Executive to any person or entity without the prior written consent of the Chairman of the Board of Directors,
Aerojet Rocketdyne Holdings, Inc., except if required by law, and to Executive’s accountants, attorneys, and spouse, provided
that they agree to maintain the confidentiality of this Agreement. Executive further represents that she has not disclosed the
terms and conditions of this Agreement to anyone other than her attorneys, accountants and spouse.

 

9.                 
The making of this Agreement is not intended, and shall not be construed, as an admission that the Releasees have violated
any federal, state or local law (statutory or decisional), ordinance or regulation, breached any contract, or committed any wrong
whatsoever against Executive.

 

10.             
The parties agree that this Agreement may not be used as evidence in a subsequent proceeding except in a proceeding to enforce
the terms of this Agreement.

 

11.             
Executive acknowledges that: (a) she has carefully read this Agreement in its entirety; (b) she has had an opportunity to
consider fully the terms of this Agreement; (c) she has been advised by the Company in writing to consult with an attorney
of her choosing in connection with this Agreement; (d) she fully understands the significance of all of the terms and conditions
of this Agreement and she has discussed it with her independent legal counsel, or has had a reasonable opportunity to do so; (e)
she has had answered to her satisfaction any questions she has asked with regard to the meaning and significance of any of the
provisions of this Agreement; and (f) she is signing this Agreement voluntarily and of her own free will and assents to all the
terms and conditions contained in this Agreement.

 

    18

    

    

12.             
This Agreement is binding upon, and shall inure to the benefit of, the parties and their respective heirs, executors, administrators,
successors and assigns.

 

13.             
If any provision of this Agreement shall be held by a court of competent jurisdiction to be illegal, void, or unenforceable,
such provision shall be of no force and effect. However, the illegality or unenforceability of such provision shall have no effect
upon, and shall not impair the enforceability of, any other provision of this Agreement; provided, however, that, upon any finding
by a court of competent jurisdiction that the release and covenants provided for by Paragraph 6 above is illegal, void, or unenforceable,
Executive agrees to execute a release, waiver and/or covenant that is legal and enforceable. Finally, any breach of the terms of
Paragraphs 6, 7 and/or 8 above shall constitute a material breach of this Agreement as to which the Company may seek appropriate
relief pursuant to Paragraph 14 below.

 

14.             
This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California,
without regard to the conflict of laws provisions thereof. Any action, suit or other legal proceeding which is commenced to resolve
any matter arising under or relating to any provision of this Agreement shall be submitted to final and binding arbitration pursuant
to the Employment Arbitration Rules of the American Arbitration Association before a single arbitrator, who is agreed upon by the
Parties, and who is a retired state or federal court judge. The arbitration shall take place in Los Angeles, California. The arbitrator
will have the authority to permit discovery and to follow the procedures that he or she determines to be appropriate, as provided
for under California law. The arbitrator will have no power to award consequential (including lost profits), punitive or exemplary
damages. Such submission to arbitrate shall be the sole and exclusive remedy available to Executive or the Company. The filing
Party shall bear filing fees for the arbitration and each Party shall bear its own legal fees and costs resulting from the arbitration,
unless a contract or statute provides for recovery to the prevailing party. The judgment on the award rendered by the arbitrator
shall be binding upon the Parties and may be entered in any court having jurisdiction. Neither party may seek judicial review of
the decision imposed by the arbitrator.

 

15.             
This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures
thereto and hereto were upon the same instrument of this Agreement.

 

16.             
This Agreement (including any exhibits attached hereto) constitutes the complete understanding between the parties with
respect to the termination of Executive’s employment at the Company and supersedes any and all agreements, understandings,
and discussions, whether written or oral, between the parties. No amendment of any provision of this Agreement shall be valid unless
the same shall be in writing and signed by each of the parties hereto.

 

[Signature page follows]

 

    19

    

    

[Signature page to Agreement and Release]

 

 

 

	 	 	 
	 	 	 
	Dated:	
	 	

	 	 	Eileen P. Drake
	 	 	 	 

 

 

	AEROJET ROCKETDYNE HOLDINGS, INC.	 	 
	 	 	 
	 	 	 
	By:	
	 	Date:	

	 	Warren G. Lichtenstein	 	 	 
	 	Executive Chairman of the Board of Directors	 	 	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    20

    

    

Exhibit B

 

Intellectual Property Prior to Employment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

21Exhibit

- 1 -

EXHIBIT 4.1
EMPLOYMENT AGREEMENT
THIS AGREEMENT made the 1st day of August, 2013.
BETWEEN:
ONCOLYTICS BIOTECH INC.
("Oncolytics")
-and-
Allison Hagerman
(the "Employee")
WHEREAS Oncolytics is engaged in the business of developing pharmaceutical products;
AND WHEREAS Oncolytics and the Employee entered into a Letter of Employment dated August 3, 2010; 
AND WHEREAS Oncolytics and the Employee wish to amend and restate the terms of employment pursuant to this Agreement;
NOW THEREFORE the parties agree as follows:
Section 1 - Definitions and Interpretation
(1)    In this Agreement the following defined terms shall have the meanings indicated:
		
	(a)
	"Business" means the business currently carried on by Oncolytics, which is the development, testing, marketing and sale of pharmaceutical products together with such additional business as Oncolytics may decide to undertake from time to time;

		
	(b)
	"Commencement Date" means August 1, 2013;

		
	(c)
	"Confidential Information" means all confidential information of Oncolytics and includes:

		
	(i)
	any data or information directly or indirectly related to the Business or arising directly or indirectly in the course of, or derived from the Employee's employment with Oncolytics whether related to products, equipment, inventions, ideas, designs, methods, systems, improvements, processes, research or otherwise;

		
	(ii)
	any of Oncolytics' technical or scientific know-how;

- 2 -

		
	(iii)
	financial and sales information, customer lists, pricing policies, lists of suppliers, proprietary computer programs in any format whatsoever, programming techniques, the manner of plans or methods of operation and the like relating to the Business;

		
	(iv)
	patent applications, drawings, blueprints, manuals, letters, notebooks, reports and all other materials (written or otherwise) related to the Business or to the agents, joint venturers or contractors of Oncolytics; and

		
	(v)
	any information provided to or received by Oncolytics on a confidential basis;

		
	(d)
	"Good Reason" means any one of the following events occurring on or after the Commencement Date:

		
	(i)
	any reduction in the Employee's then existing annual base compensation and benefits, unless comparable reductions are made for all other executive employees of Oncolytics;

		
	(ii)
	any material diminution of the Employee's duties, responsibilities, authority or reporting structure, excluding for this purpose an isolated or inadvertent action not taken in bad faith which is remedied by Oncolytics immediately after notice thereof is given by the Employee;

		
	(iii)
	any request that the Employee relocate to a work site that would increase the Employee's one-way commute distance by more than eighty (80) kilometers from the Employee's then principal residence, unless the Employee accepts such relocation opportunity; or

		
	(iv)
	any material breach by Oncolytics of its obligations under this Agreement that is not remedied within thirty (30) days of written notice of such breach from the Employee;

		
	(e)
	"Intellectual Property" means all information, data, designs, processes, software, algorithms and inventions, including those that may be the subject of patent, copyright, industrial design, trademarks, trade secret or other forms of legal protection, made, conceived or developed by the Employee during the term of employment with Oncolytics, whether alone or jointly with others and whether during or after regular working hours, that relates to or in any way pertains to or connects with any matter developed, or under investigation or development by Oncolytics or related to the Business;

- 3 -

		
	(f)
	"Termination Event" means:

		
	(i)
	breach by the Employee of any material provision of this Agreement;

		
	(ii)
	material violation by the Employee of any statutory or common law duty of loyalty to Oncolytics;

		
	(iii)
	the commission of an indictable offence by the Employee against Oncolytics; and

		
	(iv)
	personal or professional conduct of the Employee which in the reasonable and good faith judgment of Oncolytics may significantly injure Oncolytics' Business or interfere with the Employee's job performance.

(2)    This Agreement shall be governed by and construed in accordance with the laws in force in the Province of Alberta.  The parties hereby submit to the jurisdiction of the Courts of Alberta.
(3)    The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.
(4)    The following schedule is attached to and forms part of this Agreement:
Schedule "A" – Job Description
Schedule "B" – Benefits
Section 2 -     Employment
(1)    Oncolytics confirms the employment of the Employee in the position of Director, Manufacturing and Engineering and the Employee accepts the employment, starting on the Commencement Date.
(2)    The Employee shall perform the duties and responsibilities associated with the position of Director, Manufacturing and Engineering, including those set out on the Job Description attached as Schedule "A".  The Employee shall report to the Chief Operating Officer of Oncolytics.  The Employee may, from time to time, be assigned or undertake additional duties and responsibilities consistent with those generally appropriate for a Director, Manufacturing and Engineering, and the Employee's duties and responsibilities may be modified or expanded from time to time.
(3)    The Employee shall perform the duties and responsibilities set out in Section 2(2):

- 4 -

		
	(a)
	diligently, faithfully and to the best of the Employee's ability; and

		
	(b)
	in the best interests of Oncolytics.

(4)    The Employee shall comply with the terms, conditions and requirements of Oncolytics' Policy Manual, as the same may be amended, revised or added to from time to time.
Section 3 -     Remuneration
(1)    Commencing August 1, 2013, Oncolytics shall pay to the Employee a salary of $88,000 per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of $3,666.67 CANADIAN DOLLARS on the 15th and last day of each month.
(2)    Oncolytics shall, on or before the anniversary date of this Agreement in each year, evaluate and set the Employee's salary for the next ensuing year.
(3)    Oncolytics shall reimburse the Employee for all out-of-pocket expenses incurred by the Employee in the performance of the Employee's obligations under this Agreement, subject to Oncolytics' policies then in force.
(4)    Oncolytics shall be entitled to withhold from any payments made to the Employee any amounts that Oncolytics is required to withhold pursuant to any Act in force that relates to income tax, unemployment insurance premiums or pension plan premiums in any jurisdiction under which such payments are required to be made by or on behalf of the Employee, including, without limitation, the Income Tax Act (Canada), the Employment Insurance Act (Canada), the Canada Pension Plan.
Section 4 -     Benefits
The Employee shall be entitled to participate in benefit plans described in Schedule "B" and in other benefit plans instituted by Oncolytics from time to time.  
Section 5 -     Vacations
The Employee shall, in addition to all statutory holidays, be entitled to 20 days paid vacation during each twelve (12) month period of employment under this Agreement.  The Employee's vacation time shall be governed by applicable policies of Oncolytics.
Section 6 -     Place of Employment
The Employee shall perform the majority of the Employee's employment obligations from and out of Oncolytics' offices located in the City of Calgary, Alberta, Canada.

- 5 -

Section 7 -     Confidential Information
(1)    The Employee confirms that the Confidential Information is the sole and exclusive property of Oncolytics and is held by the Employee in trust for the benefit of Oncolytics.  The Employee shall use the Employee's best efforts and exercise utmost diligence to protect and safeguard the Confidential Information.  Neither during the period of employment by Oncolytics nor thereafter for a period of three years shall the Employee, directly or indirectly, use or disclose to any other person any Confidential Information, whether or not acquired, learned or obtained or developed by the Employee alone or in conjunction with others, except as such disclosure or use may be required in connection with the employment with Oncolytics or as may be agreed to in writing by Oncolytics.
(2)    Subsection 7(1) shall not apply to Confidential Information that:
		
	(a)
	is in the public domain at the time of its disclosure, or which, after disclosure, becomes part of the public domain other than by disclosure by the Employee;

		
	(b)
	the Employee can show was in the Employee's possession at the time of disclosure and was not acquired from Oncolytics; or

		
	(c)
	was received by the Employee from a third party without a covenant of confidentiality, provided such third party is under no obligation of confidentiality with respect to the Confidential Information.

(3)    The Employee shall keep informed of Oncolytics' policies and procedures for safeguarding Oncolytics' property including, without limitation, the Confidential Information and the confidentiality thereof, and will strictly comply therewith at all times.  The Employee shall not, except as required in the course of the employment with Oncolytics, remove from Oncolytics' premises any Oncolytics property including, without limitation, Confidential Information.  The Employee shall, immediately upon termination of employment with Oncolytics, return to Oncolytics all of Oncolytics' property in the Employee's possession, including, without limitation, all tangible parts of or relating to the Confidential Information as is in the Employee's possession or under the Employee's control without retaining any copies or record thereof or any other mechanical means that, alone or in combination with other means, would permit the Employee to reproduce or make available the Confidential Information.
(4)    The Employee shall advise any future employer, associate or affiliate that the Employee has signed this Agreement and is bound by its terms and conditions.
Section 8 -     Intellectual Property
(1)    The Employee confirms that any and all Intellectual Property shall be the sole and exclusive property of Oncolytics and shall be assigned by the Employee to 

- 6 -

Oncolytics.  The Employee agrees to disclose promptly to Oncolytics or its nominee any and all Intellectual Property and to execute written assignments of the Employee's right, title and interest in and to the Intellectual Property to Oncolytics or its nominee.
(2)    With respect to any Intellectual Property, the Employee also agrees:
		
	(a)
	to assist Oncolytics or its nominee in preparing any necessary copyright and patent applications, including Canadian and foreign applications, covering the Intellectual Property;

		
	(b)
	to sign and deliver all such applications and their assignment to Oncolytics or its nominee; and

		
	(c)
	generally to give all information and testimony, to co-operate with Oncolytics and its solicitors, to sign all lawful papers, and to do all lawful things that may be needed or requested by Oncolytics to obtain, extend, reissue, maintain or enforce Canadian and foreign copyrights or patents covering the Intellectual Property.

(3)    Oncolytics shall bear all expenses that are incurred in obtaining, extending, reissuing, maintaining and enforcing any and all copyrights or patents in respect of the Intellectual Property assigned to Oncolytics by the Employee, and in the vesting and perfecting of title thereto in Oncolytics and shall pay the Employee reasonable compensation for any time that Oncolytics may require the Employee to expend in order to accomplish the above subsequent to the termination of employment with Oncolytics.
(4)    The Employee hereby waives in favour of Oncolytics, all moral rights in any and all copyright works authored or co-authored by the Employee during the term of this Agreement that directly relate to the Business of Oncolytics.
Section 9 -     Term and Termination
 (1)          The Employee's employment under this Agreement shall commence on the Commencement Date and shall continue until terminated in accordance with this Section 9.
(2)          Subject to Sections 9(3), (4) and (5), and notwithstanding any other provision contained herein to the contrary, the employment relationship between the Employee and Oncolytics arising out of this Agreement shall terminate upon forty-five (45) days notice being given to Oncolytics by the Employee or immediately upon notice being given to the Employee by Oncolytics.
(3)          If Oncolytics is entitled to terminate this Agreement as the result of a Termination Event, Oncolytics shall not be required to compensate the Employee in respect of such termination or provide any period of notice in lieu of compensation with respect to such termination.

- 7 -

(4)          Subject to Section 9(5), if this Agreement is terminated by Oncolytics at any time other than pursuant to Section 9(3), or if this Agreement is terminated by the Employee for Good Reason, the Employee shall be entitled to severance payment equal to three (3) months salary. The severance payment as provided pursuant to this Section 9(4) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.
(5)          Notwithstanding Section 9(4), if there is a change of control of Oncolytics, as defined herein, and if this Agreement is terminated by Oncolytics at any time within one (1) year following the change of control other than pursuant to Section 9(3), the Employee shall be entitled to severance payment equal to twice that determined pursuant to Section 9(4).  The severance payment as provided pursuant to this Section 9(5) shall include an amount equal to the value of all benefits to which the Employee would otherwise have been entitled during the notice period.
For the purposes of this Section 9(5), “change of control” means any amalgamation, merger or other corporate reorganization which results in any change in the present effective voting control of Oncolytics, or will result in a change of the person or persons who own or control sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics, or will result in a person acquiring sufficient voting shares in Oncolytics to elect a majority of the directors of Oncolytics, or any sale, lease, exchange, partnership, or other transfer (in one transaction or a series of transactions) of all or substantially all of the assets of Oncolytics or a plan of liquidation of Oncolytics and/or an agreement for the sale or liquidation of Oncolytics is approved and completed, or the Board of Directors determines in its sole discretion that a change of control has occurred, whether or not any event described above has occurred or is contemplated. 
(6)          The Employee acknowledges and agrees that payment in lieu of notice in accordance with Section 9(4) or 9(5) shall be and is conclusively deemed to be reasonable compensation for termination of this Agreement and hereby waives any claim or potential claim that the Employee now has or may hereafter have, against Oncolytics for further severance compensation or notice other than that provided by the terms of this Agreement.
(7)     The Employee confirms that:
		
	(a)
	any breach of this Agreement or unauthorized disclosure of Confidential Information may result in irreparable harm to the Business of Oncolytics and considerable monetary damages to Oncolytics;

		
	(b)
	the damages suffered by Oncolytics may be difficult to establish; and

		
	(c)
	interim and permanent injunctions may be the only suitable remedy for Oncolytics;

- 8 -

but nothing herein shall in any way limit or restrict any other remedies available to Oncolytics at law or in equity including an action for damages.
(8)     Termination of the Employee's employment with Oncolytics for any reason whatsoever shall not terminate the Employee's obligations under Sections 7, 8 and 10 of this Agreement.
Section 10 -     Non-Competition
(1)    The Employee shall not, during the term of this Agreement, engage, hold an interest in or have any involvement, either directly or indirectly, in any business entity, venture or undertaking if such would materially interfere with or conflict with the Employee's duties and obligations to Oncolytics as provided for under this Agreement, provided that the acquisition of a non-control position in publicly traded companies will not contravene this Section.
(2)    The Employee shall not, during the term of this Agreement, and for a period of one (1) year following the termination or expiration of this Agreement, either individually or in partnership or jointly or in conjunction with any person, firm or corporation as principal, employee, partner, director or as a shareholder or investor (if actually involved in the management of a business which is competitive with the Business of Oncolytics) carry on or be engaged in any business which is directly competitive with the Business of Oncolytics.
(3)    The parties agree that all of the restrictions contained in Subsection 10(2) hereof are reasonable and valid, and that all defences to the strict enforcement thereof by Oncolytics are hereby waived by the Employee.
(4)    The Employee agrees that the remedy at law for any breach by the Employee of the provisions of this Section 10 may be inadequate and that in the event of such breach, Oncolytics may make an application to a court of competent jurisdiction for an order granting Oncolytics temporary, permanent or both kinds of injunctive relief against the Employee, without the necessity of proving actual damage to Oncolytics.
(5)    The Employee agrees that any waiver by Oncolytics of a breach of this Agreement by the Employee shall only be a waiver with respect to the particular breach giving rise to the waiver.
Section 11 -     Notices
All notices, reports, invoices, payments and formal communications (collectively referred to as "Notices") required or permitted to be given hereunder shall be in writing and shall be delivered personally or sent by prepaid registered mail or facsimile transmission to the following address or such other address as the relevant party may notify from time to time:

- 9 -

TO:    Oncolytics

ONCOLYTICS BIOTECH INC.
Suite 210, 1167 Kensington Crescent N.W.
Calgary, Alberta
T2N 1X7
Attention: President
TO:    The Employee

Allison Hagerman
[address redacted]

Notices sent by prepaid registered mail shall be deemed to be received by the addressee on the seventh day (excluding Saturdays, Sundays, Statutory Holidays and any period of postal disruption) following the mailing thereof.  Notices personally served shall be deemed to be received when actually delivered, provided such delivery shall be during normal business hours.
Section 12 -     Enurement
This Agreement shall:
		
	(a)
	replace and supercede the Letter of Employment dated August 3, 2010, and all amendments thereto; and

(b)    enure to the benefit of and be binding upon the parties hereto and:
(i)    in the case of Oncolytics, its successors and permitted assigns; and
		
	(ii)
	in the case of the Employee, her heirs, executors, administrators or other personal representatives.

IN WITNESS WHEREOF the parties have executed this Agreement as of the day and year first above written.
	
				
	ONCOLYTICS BIOTECH INC.
	 

	 
	 
	 

	 
	Per:
	/s/ Matt Coffey

	 
	 
	 

	 
	Per:
	/s/ Kirk Look

                
/s/ Clare Percival                    /s/ Allison Hagerman
Witness                        Allison Hagerman

- 1 -

SCHEDULE "A"
JOB DESCRIPTION

The Employee shall perform the duties and responsibilities associated with the position of Director, Manufacturing and Engineering.

- 1 -

SCHEDULE "B"
BENEFITS

(1)    Oncolytics shall:
		
	(a)
	commencing with the calendar year 2014 and annually thereafter, pay to the Employee's Registered Retirement Savings Plan, as directed by the Employee, an amount equal to ten (10%) percent of the Employee's annual salary as set out in Section 3(1), not to exceed the annual maximum allowable contribution.

(2)    The Employee is presently entitled to designate an additional amount equal to a maximum eight and a quarter (8.25%) percent of the Employee's annual salary to be paid by Oncolytics, on a monthly basis, into an Employee Health Trust in accordance with the provisions of the Employee Health Trust Plan currently in place, and as such provisions may be revised from time to time.
(3)    The Employee is entitled to the Physical Fitness Benefit in the amount of SEVEN HUNDRED AND FIFTY ($750.00) CANADIAN DOLLARS per annum to use towards an item or service that promotes physical activity; the details of which are outlined in the Company Policy Manual.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]